Regulatory Scrutiny Clouds Hims & Hers’ Entry into Weight-Loss Drug Market
Published on 02/06/2026 at 14:18 | Redaktion boerse-global.de
The recent foray by telehealth company Hims & Hers into the lucrative weight-loss medication sector has hit an early regulatory snag, casting doubt on what was anticipated to be a significant new revenue stream and sending its shares lower.
On Thursday, the company launched a compounded, capsule-based oral version of semaglutide. Priced aggressively at $49 for the first month and approximately $99 per month thereafter, the offering was positioned well below the cost of branded alternatives like Novo Nordisk’s Wegovy. The strategy aimed to capture market share rapidly by appealing to a broader, price-sensitive audience. The initial market reaction was notably negative for the industry’s established Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
